Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials

Abstract

Compared with etanercept, adalimumab treatment for moderate to severe plaque psoriasis was associated with greater PASI reduction, higher rates of resolution of skin signs and symptoms, and greater improvements in dermatological life quality.

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison

“…This methodology has previously been described in detail by Signorovitch et al 9 , 10 and has been widely employed to provide comparative clinical efficacy data, especially in health care technology appraisal, 11 and has previously been used to compare treatments for psoriasis where no direct comparison is available. 5 , 12 , 13 …”

“…IL-17 and IL-23 inhibitors have shown improved efficacy with higher rates of skin clearance than TNF-α inhibitors or ustekinumab in comparative studies. [1][2][3][4][5][6][7][8] However, despite the efficacy of biological therapies, many patients fail to respond initially or discontinue therapy due to loss of response over time or treatment-related adverse effects. In these patients, switching to an alternative biological agent may be an option.…”

Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials

“…Relevant clinical trials of guselkumab showed that the Psoriasis Area and Severity Index (PASI) scores were decreased significantly after treatment and showed good safety [11][12][13]. Kim et al [14] indicated that adalimumab treatment for moderate to severe plaque psoriasis was associated with greater PASI reduction, higher rates of resolution of skin signs and symptoms, and greater improvements in dermatological life quality. The studies showed that the effects of anti-IL-23p19 inhibitors were better than those of the IL-17A inhibitors, and they had a shorter induction period and a lower loading dose [15].…”

Failure of response to combination therapy of adalimumab and infliximab in a recalcitrant patient of severe psoriasis and major thalassemia: A case report

“…Tumor necrosis factor‐α is a key mediator in the pathogenesis of psoriasis. Infliximab and adalimumab, the most commonly used biologics in management of psoriasis, are TNF‐α inhibitors which have shown to reduce the disease severity and improve the quality of life . These agents are usually used alone but severe nonresponsive cases may warrant their use together as combination therapy but many times they fail to achieve the desired results.…”

“…Infliximab and adalimumab, the most commonly used biologics in management of psoriasis, are TNF-α inhibitors which have shown to reduce the disease severity and improve the quality of life. 2,3 These agents are usually used alone but severe nonresponsive cases may warrant their use together as combination therapy but many times they fail to achieve the desired results. We report a case of a 27-year-old woman who had history of 6 years for psoriasis with underlying major thalassemia, who was treated with a combination therapy of adalimumab and infliximab, who initially responded well to treatment but later became nonresponsive, which could be attributed to the presence of thalassemia.…”